Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016)

References

• Collins K, Jacks T, Pavletich NP. The cell cycle and cancer. Proc Natl Acad Sci U S A. 1997;94(7):2776–2778.
   PubMed Web of Science ®Google Scholar
• Liao Y, Feng Y, Shen J, et al. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma. Cancer Metastasis Rev. 2015. [cited 2015 Dec 15]. DOI:10.1007/s10555-015-9601-1.
   Web of Science ®Google Scholar
• Murray AW. Recycling the cell cycle: cyclins revisited. Cell. 2004;116(2):221–234.
   PubMed Web of Science ®Google Scholar
• Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014;15(6):122.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Harlow E, Hunt T, et al. Cyclin-dependent kinases: a family portrait. Nat Cell Biol. 2009;11(11):1275–1276.
   PubMed Web of Science ®Google Scholar
• Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140(15):3079–3093.
   PubMed Web of Science ®Google Scholar
• Cheung ZH, Ip NY. Cdk5: a multifaceted kinase in neurodegenerative diseases. Trends Cell Biol. 2012;22(3):169–175.
   PubMed Web of Science ®Google Scholar
• Arif A. Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase Cdk5. Biochem Pharmacol. 2012;84(8):985–993.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1(3):222–231.
   PubMed Web of Science ®Google Scholar
• Jt R, Ky K, Jo B, et al. mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert). Nature. 2014;510(7505):393–396.
   PubMed Web of Science ®Google Scholar
• Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell. 1997;8(2):287–301.
   PubMed Web of Science ®Google Scholar
• Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res. 2014;20(13):3379–3383.
   PubMed Web of Science ®Google Scholar
• Santamaria D, Barriere C, Cerqueira A, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007;448(7155):811–815.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–166.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Sotillo R, Santamaria D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004;118(4):493–504.
   PubMed Web of Science ®Google Scholar
• Rzymski T, Mikula M, Wiklik K, et al. CDK8 kinase--An emerging target in targeted cancer therapy. Biochim Biophys Acta. 2015;1854(10 Pt B):1617–1629.
   PubMed Web of Science ®Google Scholar
• Larochelle S, Amat R, Glover-Cutter K, et al. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol. 2012;19(11):1108–1115.
   PubMed Web of Science ®Google Scholar
• Carlsten JO, Zhu X, Gustafsson CM. The multitalented mediator complex. Trends Biochem Sci. 2013;38(11):531–537.
   PubMed Web of Science ®Google Scholar
• Egly JM, Coin F. A history of TFIIH: two decades of molecular biology on a pivotal transcription/repair factor. DNA Repair (Amst). 2011;10(7):714–721.
   PubMed Web of Science ®Google Scholar
• Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8(7):547–566.
   PubMed Web of Science ®Google Scholar
• Tigan AS, Bellutti F, Kollmann K, et al. CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene. 2015. [cited 2015 Oct 26]. DOI:10.1038/onc.2015.407.
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–146.
   PubMed Web of Science ®Google Scholar
• Peyressatre M, Prevel C, Pellerano M, et al. Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors. Cancers (Basel). 2015;7(1):179–237.
   PubMed Web of Science ®Google Scholar
• Morgan DO. Principles of CDK regulation. Nature. 1995;374(6518):131–134.
   PubMed Web of Science ®Google Scholar
• Vidula N, Rugo HS. Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast cancer: a review of preclinical and clinical data. Clin Breast Cancer. 2016;16(1):8–17.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. Oncogene. 2013;33(15):1890–1903.
   PubMed Web of Science ®Google Scholar
• Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol. 1994;14(3):2077–2086.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005;30(11):630–641.
   PubMed Web of Science ®Google Scholar
• Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006;9(1):23–32.
   PubMed Web of Science ®Google Scholar
• Reddy HK, Mettus RV, Rane SG, et al. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res. 2005;65(22):10174–10178.
   PubMed Web of Science ®Google Scholar
• Schwartz R, Engel I, Fallahi-Sichani M, et al. Gene expression patterns define novel roles for E47 in cell cycle progression, cytokine-mediated signaling, and T lineage development. Proc Natl Acad Sci U S A. 2006;103(26):9976–9981.
   PubMed Web of Science ®Google Scholar
• Nagel S, Leich E, Quentmeier H, et al. Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma. Leukemia. 2008;22(2):387–392.
   PubMed Web of Science ®Google Scholar
• Hu MG, Deshpande A, Enos M, et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res. 2009;69(3):810–818.
   PubMed Web of Science ®Google Scholar
• Matushansky I, Radparvar F, Skoultchi AI. CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells. Oncogene. 2003;22(27):4143–4149.
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Anderson K, Jacobsen SE, et al. Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction. Embo J. 2007;26(9):2361–2370.
   PubMed Web of Science ®Google Scholar
• Handschick K, Beuerlein K, Jurida L, et al. Cyclin-dependent kinase 6 is a chromatin-bound cofactor for NF-kappaB-dependent gene expression. Mol Cell. 2014;53(2):193–208.
   PubMed Web of Science ®Google Scholar
• Uras IZ, Walter GJ, Scheicher R, et al. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. 2016;127(23):2890–2902.
   PubMed Web of Science ®Google Scholar
• Wagner K, Damm F, Thol F, et al. FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. Haematologica. 2011;96(5):681–686.
   PubMed Web of Science ®Google Scholar
• Kollmann K, Heller G, Schneckenleithner C, et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013;24(2):167–181.
   PubMed Web of Science ®Google Scholar
• Scheicher R, Hoelbl-Kovacic A, Bellutti F, et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood. 2015;125(1):90–101.
   PubMed Web of Science ®Google Scholar
• Placke T, Faber K, Nonami A, et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014;124(1):13–23.
   PubMed Web of Science ®Google Scholar
• Lim JT, Mansukhani M, Weinstein IB. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci U S A. 2005;102(14):5156–5161.
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Eichhorn PJ, Cortes J, et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A. 2011;108(9):3761–3766.
   PubMed Web of Science ®Google Scholar
• Caldon CE, Sergio CM, Kang J, et al. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther. 2012;11(7):1488–1499.
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24(11):1770–1783.
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 2005;23(36):9408–9421.
   PubMed Web of Science ®Google Scholar
• Pozo K, Castro-Rivera E, Tan C, et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell. 2013;24(4):499–511.
   PubMed Web of Science ®Google Scholar
• Chipumuro E, Marco E, Cl C, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159(5):1126–1139.
   PubMed Web of Science ®Google Scholar
• Christensen CL, Kwiatkowski N, Abraham BJ, et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 2014;26(6):909–922.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511(7511):616–620.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang T, Kwiatkowski N, et al. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell. 2015;163(1):174–186.
   PubMed Web of Science ®Google Scholar
• Krystof V, Baumli S, Furst R. Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target. Curr Pharm Des. 2012;18(20):2883–2890.
   PubMed Web of Science ®Google Scholar
• Lee DK, Duan HO, Chang C. Androgen receptor interacts with the positive elongation factor P-TEFb and enhances the efficiency of transcriptional elongation. J Biol Chem. 2001;276(13):9978–9984.
   PubMed Web of Science ®Google Scholar
• Gordon V, Bhadel S, Wunderlich W, et al. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol. 2010;24(12):2267–2280.
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Kramer MP. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications. Expert Opin Investig Drugs. 2011;20(12):1611–1628.
   PubMed Web of Science ®Google Scholar
• Trowbridge JM, Rogatsky I, Garabedian MJ. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci U S A. 1997;94(19):10132–10137.
   PubMed Web of Science ®Google Scholar
• Rogatsky I, Trowbridge JM, Garabedian MJ. Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem. 1999;274(32):22296–22302.
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Mauritz M. Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond. Future Med Chem. 2016;8(1):55–72.
   PubMed Web of Science ®Google Scholar
• Knuesel MT, Meyer KD, Bernecky C, et al. The human CDK8 subcomplex is a molecular switch that controls mediator coactivator function. Genes Dev. 2009;23(4):439–451.
   PubMed Web of Science ®Google Scholar
• Firestein R, Shima K, Nosho K, et al. CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. Int J Cancer. 2010;126(12):2863–2873.
   PubMed Web of Science ®Google Scholar
• Firestein R, Bass AJ, Kim SY, et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008;455(7212):547–551.
   PubMed Web of Science ®Google Scholar
• Porter DC, Farmaki E, Altilia S, et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc Natl Acad Sci U S A. 2012;109(34):13799–13804.
   PubMed Web of Science ®Google Scholar
• Putz EM, Gotthardt D, Hoermann G, et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep. 2013;4(3):437–444.
   PubMed Web of Science ®Google Scholar
• Li N, Fassl A, Chick J, et al. Cyclin C is a haploinsufficient tumour suppressor. Nat Cell Biol. 2014;16(11):1080–1091.
   PubMed Web of Science ®Google Scholar
• Healy S, Khan P, Davie JR. Immediate early response genes and cell transformation. Pharmacol Ther. 2013;137(1):64–77.
   PubMed Web of Science ®Google Scholar
• Villicana C, Cruz G, Zurita M. The basal transcription machinery as a target for cancer therapy. Cancer Cell Int. 2014;14(1):18.
   PubMed Web of Science ®Google Scholar
• Koumenis C, Giaccia A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol. 1997;17(12):7306–7316.
   PubMed Web of Science ®Google Scholar
• Bywater MJ, Poortinga G, Sanij E, et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell. 2012;22(1):51–65.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan SK, Gartel AL. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res. 2006;66(6):3264–3270.
   PubMed Web of Science ®Google Scholar
• Kaichi S, Takaya T, Morimoto T, et al. Cyclin-dependent kinase 9 forms a complex with GATA4 and is involved in the differentiation of mouse ES cells into cardiomyocytes. J Cell Physiol. 2011;226(1):248–254.
   PubMed Web of Science ®Google Scholar
• Adler AS, McCleland ML, Truong T, et al. CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Res. 2012;72(8):2129–2139.
   PubMed Web of Science ®Google Scholar
• Derheimer FA, Chang CW, Ljungman M. Transcription inhibition: a potential strategy for cancer therapeutics. Eur J Cancer. 2005;41(16):2569–2576.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen X, Chen Y, et al. Antitumor activity of novel chimeric peptides derived from cyclinD/CDK4 and the protein transduction domain 4. Amino Acids. 2013;44(2):499–510.
   PubMed Web of Science ®Google Scholar
• Bozhenko VK, Kulinich TM, Kudinova EA et al. New targeted anti CDK4/6 peptide MM-D37K. J Clin Oncol 31, 2013 (suppl; abstr e13545)
   Google Scholar
• Novel CDK4/6 inhibitors based on P16 peptide technology platform. International Congress Targeted Anticancer Therapy 2014 final program. [ cited 2016 Mar 1] Available from: http://tatcongress.org/wp-content/uploads/2014/05/tat2014-abstracts-poster-session-2_140217.pdf
   Google Scholar
• Losiewicz MD, Carlson BA, Kaur G, et al. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun. 1994;201(2):589–595.
   PubMed Web of Science ®Google Scholar
• Cimini A, d’Angelo M, Benedetti E, et al. Flavopiridol: an old drug with new perspectives? Implication for development of new drugs. J Cell Physiol. 2016. [cited May 2016 12]. DOI:10.1002/jcp.25421.
   Google Scholar
• Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997;243(1–2):527–536.
   PubMedGoogle Scholar
• Cicenas J, Kalyan K, Sorokinas A, et al. Roscovitine in cancer and other diseases. Ann Transl Med. 2015;3(10):135.
   PubMed Web of Science ®Google Scholar
• Cirstea D, Hideshima T, Santo L, et al. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013;27(12):2366–2375.
   PubMed Web of Science ®Google Scholar
• Brasca MG, Amboldi N, Ballinari D, et al. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-py razolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009;52(16):5152–5163.
   PubMed Web of Science ®Google Scholar
• Degrassi A, Russo M, Nanni C, et al. Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging. Mol Cancer Ther. 2010;9(3):673–681.
   PubMed Web of Science ®Google Scholar
• Albanese C, Alzani R, Amboldi N, et al. Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier. Br J Pharmacol. 2013;169(1):156–166.
   PubMed Web of Science ®Google Scholar
• Siemeister G, Lucking U, Am W, et al. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Mol Cancer Ther. 2012;11(10):2265–2273.
   PubMed Web of Science ®Google Scholar
• Hamilton G, Klameth L, Rath B, et al. Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines. Molecules. 2014;19(2):2077–2088.
   PubMed Web of Science ®Google Scholar
• Squires MS, Feltell RE, Wallis NG, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther. 2009;8(2):324–332.
   PubMed Web of Science ®Google Scholar
• Chen EX, Hotte S, Hirte H, et al. A phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. Br J Cancer. 2014;111(12):2262–2267.
   PubMed Web of Science ®Google Scholar
• Goh KC, Novotny-Diermayr V, Hart S, et al. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia. 2012;26(2):236–243.
   PubMed Web of Science ®Google Scholar
• Tragara’s TG02 is Highly Active in CLL Cells Derived from Patients who have Failed Treatment with Ibrutinib. [cited 2016 Mar 1] Available from: http://www.tragarapharma.com/OSU%20Data%20PR%20FINAL.pdf
   Google Scholar
• Tragara Pharmaceuticals Initiates Phase I Clinical Program for TG02. [cited 2016 Mar 1] Available from: http://www.prnewswire.com/news-releases/tragara-pharmaceuticals-initiates-phase-i-clinical-program-for-tg02-102523374.html
   Google Scholar
• Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016;18(1):17.
   PubMed Web of Science ®Google Scholar
• Reddy MV, Akula B, Cosenza SC, et al. Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrid o[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5). J Med Chem. 2014;57(3):578–599.
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3(11):1427–1438.
   PubMed Web of Science ®Google Scholar
• Toogood PL, Harvey PJ, Repine JT, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem. 2005;48(7):2388–2406.
   PubMed Web of Science ®Google Scholar
• FDA Approves new Indication for fulvestrant for women with HR+, HER2- metastatic breast cancer. [cited 2016 Mar 10] Available from: http://www.businesswire.com/news/home/20160302006589/en/FDA-Approves-Indication-FASLODEX%C2%AE-fulvestrant
   Google Scholar
• Sanchez-Martinez C, Gelbert LM, Lallena MJ, et al. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorg Med Chem Lett. 2015;25(17):3420–3435.
   PubMed Web of Science ®Google Scholar
• Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013;31(16):2024–2028.
   PubMed Web of Science ®Google Scholar
• Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825–837.
   PubMed Web of Science ®Google Scholar
• AACR-NCI-EORTC. Symposium on molecular target and cancer therapeutics. Boston (MA): AACR; 2013. p. Abstract C88.
   Google Scholar
• Rader J, Russell MR, Hart LS, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013;19(22):6173–6182.
   PubMed Web of Science ®Google Scholar
• Vora SR, Juric D, Kim N, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 2014;26(1):136–149.
   PubMed Web of Science ®Google Scholar
• Li C, Liu L, Liang L, et al. AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia. Mol Cancer Ther. 2015;14(2):375–383.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang X, Eksterowicz J, et al. Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3. J Med Chem. 2014;57(8):3430–3449.
   PubMed Web of Science ®Google Scholar
• Keegan K, Li C, Li Z, et al. Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia. Mol Cancer Ther. 2014;13(4):880–889.
   PubMed Web of Science ®Google Scholar
• 105th AACR Annual Meeting. AACR annual meeting. Washington (DC): AACR; 2014. p. Abstract 4519.
   Google Scholar
• Malinkova V, Vylicil J, Krystof V. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014). Expert Opin Ther Pat. 2015;25(9):953–970.
   PubMed Web of Science ®Google Scholar
• Schiemann K, Mallinger A, Wienke D, et al. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore. Bioorg Med Chem Lett. 2016;26(5):1443–1451.
   PubMed Web of Science ®Google Scholar
• Mallinger A, Crumpler S, Pichowicz M, et al. Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. J Med Chem. 2015;58(4):1717–1735.
   PubMed Web of Science ®Google Scholar
• Rzymski T, Zarebski A, Dreas A, et al. Substituted tricyclic benzimidazoles as kinase inhibitor. WO2014072435 (2014)
   Google Scholar
• Robinson IB, Porter DC, Wentland MP Cdk8/cdk19 selective inhibitors and their use in antimetastatic and chemopreventative methods for cancer. WO2013116786 (2013)
   Google Scholar
• Broude E, Roninson IB Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer. WO2014134169 (2014)
   Google Scholar
• Cai D, Latham VM Jr., Zhang X, et al. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res. 2006;66(18):9270–9280.
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689–698.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhu YH, Mao CQ, et al. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles. J Control Release. 2014;192:114–121.
   PubMed Web of Science ®Google Scholar
• Huang CH, Lujambio A, Zuber J, et al. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014;28(16):1800–1814.
   PubMed Web of Science ®Google Scholar
• Bommi-Reddy A, Almeciga I, Sawyer J, et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A. 2008;105(43):16484–16489.
   PubMed Web of Science ®Google Scholar
• Espacenet, free european patent database search engine. [cited 2016 Mar 10] Available from: http://worldwide.espacenet.com
   Google Scholar